Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Mykola I. Onyshchenko

Oncology
Billings Clinic Cancer Center
801 N 29th St, 
Billings, MT 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Billings Clinic Cancer Center
801 N 29th St, 
Billings, MT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mykola Onyshchenko is an Oncologist in Billings, Montana. Dr. Onyshchenko is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Onyshchenko is currently accepting new patients.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Glendive Medical Center
Billings Clinic
Beartooth Billings Clinic
Stillwater Billings Clinic
Livingston Healthcare
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Billings Clinic Cancer Center
801 N 29th St, Billings, MT 59101
Call: 406-238-2500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
Enrollment Status: Terminated
Publish Date: March 05, 2024
Intervention Type: Drug
Study Drugs: Capmatinib, Pemetrexed, Cisplatin, Carboplatin, Osimertinib
Study Phase: Phase 3
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

18 Total Publications

Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
Journal: Clinical lung cancer
Published: June 02, 2023
View All 18 Publications
Similar Doctors
Michael T. Kidd
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael T. Kidd
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael T. Kidd
Hematology Oncology | Hematology | Oncology

Billings Clinic

801 N 29th St, 
Billings, MT 
 (0.1 miles away)
406-238-2500
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Kidd is a Hematologist Oncology specialist and a Hematologist in Billings, Montana. Dr. Kidd has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Breast Cancer in Men, Paget Disease of the Breast, and Chronic Lymphocytic Leukemia (CLL).

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Kristina M. Hool
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Kristina M. Hool
Hematology Oncology | Hematology | Oncology

Scl Health Montana

1315 Golden Valley Cir, 
Billings, MT 
 (4.0 miles away)
406-238-6290
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kristina Hool is a Hematologist Oncology specialist and a Hematologist in Billings, Montana. Dr. Hool is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Astrocytoma, and Embryonal Tumor with Multilayered Rosettes. Dr. Hool is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Patrick W. Cobb
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Patrick W. Cobb
Hematology Oncology | Hematology | Oncology
1315 Golden Valley Cir, 
Billings, MT 
 (4.0 miles away)
406-238-6290
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Cobb is a Hematologist Oncology specialist and a Hematologist in Billings, Montana. Dr. Cobb is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Cobb is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Onyshchenko's expertise for a condition
ConditionClose
    • Distinguished
    • Lung Cancer
      Dr. Onyshchenko is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Pleuropulmonary Blastoma
      Dr. Onyshchenko is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Small Cell Lung Cancer (SCLC)
      Dr. Onyshchenko is
      Distinguished
      . Learn about Small Cell Lung Cancer (SCLC).
      See more Small Cell Lung Cancer (SCLC) experts
    • Advanced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Onyshchenko is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Onyshchenko is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Large-Cell Lung Carcinoma
      Dr. Onyshchenko is
      Advanced
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    • Lung Adenocarcinoma
      Dr. Onyshchenko is
      Advanced
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Non-Small Cell Lung Cancer (NSCLC)
      Dr. Onyshchenko is
      Advanced
      . Learn about Non-Small Cell Lung Cancer (NSCLC).
      See more Non-Small Cell Lung Cancer (NSCLC) experts
    • Squamous Cell Lung Carcinoma
      Dr. Onyshchenko is
      Advanced
      . Learn about Squamous Cell Lung Carcinoma.
      See more Squamous Cell Lung Carcinoma experts
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Onyshchenko is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Ampullary Cancer
      Dr. Onyshchenko is
      Experienced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Anaplastic Thyroid Cancer
      Dr. Onyshchenko is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Angiosarcoma
      Dr. Onyshchenko is
      Experienced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Antiphospholipid Syndrome
      Dr. Onyshchenko is
      Experienced
      . Learn about Antiphospholipid Syndrome.
      See more Antiphospholipid Syndrome experts
    • Bone Tumor
      Dr. Onyshchenko is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved